转移性肾细胞癌的最佳一线治疗:网络荟萃分析

IF 1.1 Q4 ONCOLOGY

Kidney Cancer Pub Date : 2018-08-01 DOI:10.3233/KCA-180032

A. Hahn, P. Hale, B. Maughan, B. Haaland, N. Agarwal

{"title":"转移性肾细胞癌的最佳一线治疗:网络荟萃分析","authors":"A. Hahn, P. Hale, B. Maughan, B. Haaland, N. Agarwal","doi":"10.3233/KCA-180032","DOIUrl":null,"url":null,"abstract":"Background: First-line treatment of metastatic renal cell carcinoma (mRCC) has incrementally evolved over the past decade. Most recently, promising clinical trials for first-line cabozantinib, nivolumab plus ipilimumab, and bevacizumab plus atezolizumab were reported. However, the comparator arm in all of these trials was sunitinib, so no head-to-head comparison exists for contemporary first-line treatments. Objective: To provide an indirect comparison of first-line treatments for mRCC that are currently approved or likely soon","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/KCA-180032","citationCount":"1","resultStr":"{\"title\":\"Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis\",\"authors\":\"A. Hahn, P. Hale, B. Maughan, B. Haaland, N. Agarwal\",\"doi\":\"10.3233/KCA-180032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: First-line treatment of metastatic renal cell carcinoma (mRCC) has incrementally evolved over the past decade. Most recently, promising clinical trials for first-line cabozantinib, nivolumab plus ipilimumab, and bevacizumab plus atezolizumab were reported. However, the comparator arm in all of these trials was sunitinib, so no head-to-head comparison exists for contemporary first-line treatments. Objective: To provide an indirect comparison of first-line treatments for mRCC that are currently approved or likely soon\",\"PeriodicalId\":17823,\"journal\":{\"name\":\"Kidney Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2018-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3233/KCA-180032\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/KCA-180032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/KCA-180032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

背景：转移性肾细胞癌（mRCC）的一线治疗在过去十年中逐渐发展。最近，有报道称，一线卡博替尼、尼沃单抗加易普利单抗和贝伐单抗加atezolizumab的临床试验前景看好。然而，所有这些试验中的对照组都是舒尼替尼，因此当代一线治疗不存在正面比较。目的：对目前批准或可能很快批准的mRCC一线治疗方法进行间接比较

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis

Background: First-line treatment of metastatic renal cell carcinoma (mRCC) has incrementally evolved over the past decade. Most recently, promising clinical trials for first-line cabozantinib, nivolumab plus ipilimumab, and bevacizumab plus atezolizumab were reported. However, the comparator arm in all of these trials was sunitinib, so no head-to-head comparison exists for contemporary first-line treatments. Objective: To provide an indirect comparison of first-line treatments for mRCC that are currently approved or likely soon

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Kidney Cancer Multiple-

CiteScore

0.90

自引率

8.30%

发文量